SCHEMBL1198568

SCHEMBL1198568

COc1ccc(-c2csc(Cn3cc(C(=O)O)cn3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.56
RAB9A P51151 5/20 0.56
NPC1 O15118 4/20 0.56
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
KDM4E B2RXH2 2/20 0.56
MAPT P10636 4/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KMT2A Q03164 6/20 0.51
POLB P06746 1/20 0.51
PKM P14618 1/20 0.51
OPRK1 P41145 1/20 0.51
CSNK2A1 P68400 1/20 0.51
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1197517 0.89 CSNK2A1 (0.53) MEN1RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL12876399 0.87 RAB9A (0.53) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL1198524 0.87 MEN1 (0.52) MEN1RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL1198915 0.87 RAB9A (0.51) MEN1RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL12876017 0.86 MEN1 (0.41) MEN1RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL1198610 0.86 RAB9A (0.46) MEN1RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL27806579 0.86 KDM4E (0.50) MEN1RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL1199316 0.85 RAB9A (0.53) MEN1RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL1198867 0.85 RAB9A (0.47) MEN1RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL1198836 0.83 RXRA (0.42) MEN1RAB9ANPC1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MEN1 2661/4885RAB9A 2507/4885NPC1 3877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.